搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
2 天
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the ...
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
3 天
on MSN
Evotec and Novo Nordisk in technology development partnership
(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...
1 天
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
4 天
on MSN
Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulin
Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...
9 天
诺和诺德下一代减肥药monlunabant试验减重效果不佳 股价大跌5%
丹麦制药公司 诺和诺德 ( Novo Nordisk A/S )周五报告称,该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限,而且有一定副作用,导致该公司股价周五下跌。
11 天
诺和诺德达成6亿美元合作,布局肝外LNP递送技术
▎药明康德内容团队编辑NanoVation Therapeutics今日宣布与诺和诺德(Novo Nordisk)达成一项多年研发合作伙伴关系,旨在推进针对心脏代谢性疾病和罕见病的创新基因药物(genetic ...
2 天
Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
9 天
诺和诺德减肥药试验数据令人失望 股价下跌逾6%
周五早间 诺和诺德 Novo Nordisk股价一度下跌逾6%,此前有媒体报道称其减肥药的试验数据不佳。在减肥药物领域,诺和诺德面临着来自多家小公司和罗氏等制药巨头越来越激烈的竞争。
2 天
Senator Bernie Sanders grills the top executive of Novo Nordisk over high drug prices
The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.
1 天
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major ...
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...
Radio France Internationale
18 天
研究:减肥药善纤达对12岁以下儿童大致安全有效
(法新社巴黎11日电) 今天发布的1份小型研究报告显示,丹麦大药厂诺和诺德(Novo Nordisk)的减肥药善纤达(Saxenda)对有肥胖症的12岁以下儿童大致安全且有效。这份结果受到外部专家审慎欢迎。
证券之星
13 天
坎托菲茨杰拉德公司:重申Novo Nordisk(NVO.US)评级
坎托菲茨杰拉德公司:重申Novo Nordisk(NVO.US)评级,由增持调整至增持评级, 目标价由160.00美元调整至160.00美元。 诺和诺德(NVO.US)公司简介:诺和诺德公司成立于1923年,是一家全球领先的生物制药公司,总部位于丹麦。其目标是推动变革,战胜糖尿病和其他严重 ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈